Blueprint Medicines

Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Endpoints
Loxo Oncology
Blueprint Medicines
medullary thyroid cancer
LOXO-292
BLU-667
Flag link:
Blueprint Medicines unveils preclinical data for rare bone disease program
Blueprint Medicines unveils preclinical data for rare bone disease program
BioCentury
Blueprint Medicines
BLU-782
fibrodysplasia
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:
Alexion leaves Moderna, others behind in R&D shake-up
Alexion leaves Moderna, others behind in R&D shake-up
BioPharma Dive
Alexion
Moderna Therapeutics
Arbutus BioPharma
Blueprint Medicines
R&D
Flag link:
Blueprint plots a $100M IPO for its precision medicine platform
Blueprint plots a $100M IPO for its precision medicine platform
Fierce Biotech
Blueprint Medicines
IPOs
Flag link:
Alexion bets up to $265M on Blueprint's precision medicine platform
Alexion bets up to $265M on Blueprint's precision medicine platform
Fierce Biotech
Alexion
precision medicine
Blueprint Medicines
Flag link:
FierceBiotech's 2011 Fierce 15 Biotech Companies
FierceBiotech's 2011 Fierce 15 Biotech Companies
Fierce Biotech
Blueprint Medicines
Cerulean
Cerenis Therapeutics
Epizyme
Forma Therapeutics
Intrexon
Merrimack Pharmaceuticals
f-star
Pfenex
Pearl Therapeutics
Reata
Selecta
Rib-X Pharmaceuticals
Tesaro
Theraclone
Flag link: